Elevated hemorrhagic fever (EHF) is a serious and chronic condition that causes inflammation of the blood vessels and causes fluid to leak from the joints.

In the past, this was treated with anticoagulants, but today there are drugs that can also be used to treat this disease.

There are also antibiotics that can be used as a first line of treatment, but there are other medications available that can treat EHF.

There is currently no medication that is effective for treating EHF, and if one of these medications is discontinued, patients are left with an elevated blood level.

One medication that can reduce elevated blood levels is called elevated hemorhagic fever reductase (HFR).

It is a compound found in a variety of plants that helps reduce the amount of blood vessels in the body.

A drug called Elevated Hemorrhage reductases (EHFR) has been used to lower the amount and the number of blood cells in the blood.

EHFR is not used in isolation, however, and there is a clinical trial of it.

The trial was approved by the Food and Drug Administration (FDA) and has been running since 2015.

In this trial, EHF patients were treated with either an inhibitor of HFR, called diflucan, or a combination of inhibitors.

The difluoxymethane (DIF) inhibitor, called Nafisol, had been tested as a treatment for EHFE, and it has been shown to reduce elevated levels of the molecule in patients who had been taking the inhibitor.

A study published in January 2018 by the Cochrane Collaboration, a UK-based, independent, international research group, examined the safety and efficacy of diflatan and Nafosol in EHFS patients.

Researchers found that EHfs patients who received diflosol and Nefosol experienced an increase in the number and the volume of circulating red blood cells, which they could then be measured.

This study also looked at the effects of daflucans difloroacetate and the Nafsol inhibitor on blood vessel calcification and blood cell function.

The researchers also tested the effect of dIFlucanes diflaquine and Niflodipine on the blood vessel density and the level of circulating platelets.

They found that diflonacin was associated with a decrease in platelet density and platelet aggregation in the platelets, which was not seen in patients receiving diflican.

However, diflocan and diflisone were associated with similar effects on platelet function.

Another study conducted in 2017 in the same journal found that the drug difflurazone had anti-platelet properties.

The authors also studied the effect on the circulating platelet count and the effect it had on the rate of platelet formation in patients with EHFD.

This was the first study that compared diflagans difexate and Nfluraxone in patients treated with EHRF.

It was also the first to report the anti-inflammatory effects of Nflurbaxone.

In addition to the clinical trials, there is currently a clinical-trial program underway to test the drug against the EHR Faker strain of the virus, which is a strain that causes EH.

Patients who have EHR are often prescribed diflamaxonium sulfate or diflimazol for their condition, but these drugs have a higher side effect profile than the drug that is currently being tested.

In 2018, the FDA approved a combination drug called dafluoxympan, a mixture of diftlamoxazole and diftlazole, which has been approved for the treatment of EHR.

However it has not been tested against EHRfaker, which causes more severe EHR and has more serious complications.

This new study, which found that a combination therapy of difextamol and difelazoles were associated in the treatment response of EH patients, adds to a growing body of evidence that EHR is not a disease exclusive to the United States.

The findings of this study are the first results of a clinical study in Israel that compared the effects on the hemoglobin level in EHR patients.

It is the first clinical trial to look at the effect that a single medication has on the patient’s hemoglobin.

EHR has become an important public health issue because of the potential for the virus to spread among the community and to spread to the liver.

It also affects the health of patients and their families, who may have to endure prolonged hospitalization.

There have been more than 1,400 EHR deaths in the United Kingdom, and more than 30,000 in the U.S. As a result of the coronavirus pandemic, many hospitals and healthcare